Freshly Printed - allow 10 days lead
Couldn't load pickup availability
Outsourcing Biopharma R&D to India
P R Chowdhury (Author)
9780081017340, Elsevier Science
Paperback / softback, published 19 August 2016
130 pages
23.3 x 15.6 x 1 cm, 0.2 kg
The trend of outsourcing to India for research and development is catching on fast. Over the last decade, worldwide pharmaceutical and biotechnology companies have made India their choice for a research destination. Initially R&D was inclined more towards developing products for the Indian market within the country. This led to several multinational companies opening up production plants in India, primarily due to the globalization of the Indian economy and offshoring jobs to India. Alongside, several global pharma-biotech majors ascertained large market requirements within the country and capitalized on the advantage of serving Indian customers. Strategies were devised to optimize operational expenses with the setting up of on-site R&D to develop products for local requirements. In view of this, this book seeks to explore various nuances of the outsourcing sector with respect to biopharma in India.
Acknowledgements About the author Chapter 1: Biopharma outsourcing in India: its evolution Abstract: 1.1 What is outsourcing? 1.2 What is R&D? 1.3 Organisational patterns in R&D outsourcing 1.4 R&D outsourcing in the pharmaceutical industry 1.5 India as the emerging hub of R&D outsourcing in the pharmaceutical industry 1.6 Outsourcing models prevalent in India: cooperation models for outsourced services 1.7 Key issues involved in outsourcing Chapter 2: India’s core competitive advantage in R&D in the biopharma sector: the impetus for outsourcing Abstract: 2.1 Introduction 2.2 Cost competitiveness 2.3 Resources and skill 2.4 The role of the government 2.5 Conclusion Chapter 3: Different modes of outsourcing biopharma R&D to India Abstract: 3.1 Indian companies involved in outsourcing activities6 3.2 Contract research services 3.3 Contract manufacturing organisations 3.4 Drug substance manufacturing 3.5 Drug product manufacturing 3.6 Process development 3.7 Analytical methods and characterisation 3.8 Business models for contract manufacturing organisations 3.9 Insights into outsourcing of product development and manufacture 3.10 Clinical trials 3.11 Advantages and disadvantages of doing clinical trials in India 3.12 Active pharmaceutical ingredient and technology transfer 3.13 Conclusions and implications Chapter 4: The Indian regulatory environment: a historical perspective Abstract: 4.1 Indian Council for Medical Research 4.2 Central Drugs Standard Control Organisation 4.3 Department of Biotechnology 4.4 National Pharmaceutical Pricing Authority 4.5 Overview of the industry Chapter 5: Implications of the changing regulatory environment in India Abstract: 5.1 Introduction 5.2 Capacity Building Programme: recent development5 5.3 Clinical Trials Registry – India11 5.4 The Indian Society for Clinical Research12 5.6 Conclusion Chapter 6: Creating contracts for outsourcing in the biopharma industry Abstract: 6.1 Biopharma outsourcing 6.2 Preliminary documentation 6.3 Drafting of the biopharma outsourcing agreement 6.4 Specific considerations in different types of agreements 6.5 Conclusion Chapter 7: Environmental, health and safety guidelines and biopharma outsourcing: an Indian perspective Abstract: 7.1 Introduction 7.2 The environmental, health and safety guidelines 7.3 EHS guidelines and India 7.4 Challenges faced by Indian companies in EHS compliance 7.5 Conclusion Chapter 8: Certifications Abstract: 8.1 Introduction 8.2 Certifications 8.3 Manufacturing licence 8.4 Good Manufacturing Practices 8.5 No-Objection Certificate and Certificate of Origin 8.6 Certificate of a Pharmaceutical Product 8.7 Certifications for clinical trials 8.8 International regulatory certifications 8.9 Conclusion Chapter 9: The need for due diligence of service providers Abstract: 9.1 Introduction 9.2 Sources utilised prior to due diligence 9.3 Areas of due diligence 9.4 Due diligence process 9.5 Contents of the due diligence report6 9.6 Conclusion Index
Subject Areas: Pharmacology [MMG], Pharmaceutical industries [KNDP]
